vs
Beam Therapeutics Inc.（BEAM）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是Beam Therapeutics Inc.的1.6倍（$185.1M vs $114.1M），Beam Therapeutics Inc.净利率更高（214.1% vs 33.3%，领先180.8%），Beam Therapeutics Inc.同比增速更快（279.5% vs 9.8%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
BEAM vs DOCS — 直观对比
营收规模更大
DOCS
是对方的1.6倍
$114.1M
营收增速更快
BEAM
高出269.8%
9.8%
净利率更高
BEAM
高出180.8%
33.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $185.1M |
| 净利润 | $244.3M | $61.6M |
| 毛利率 | — | 89.9% |
| 营业利润率 | -15.3% | 38.9% |
| 净利率 | 214.1% | 33.3% |
| 营收同比 | 279.5% | 9.8% |
| 净利润同比 | 370.4% | -18.1% |
| 每股收益（稀释后） | $2.53 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMDOCS
| Q4 25 | $114.1M | $185.1M | ||
| Q3 25 | — | $168.5M | ||
| Q2 25 | — | $145.9M | ||
| Q1 25 | — | $138.3M | ||
| Q4 24 | — | $168.6M | ||
| Q3 24 | — | $136.8M | ||
| Q2 24 | — | $126.7M | ||
| Q1 24 | — | $118.1M |
净利润BEAMDOCS
| Q4 25 | $244.3M | $61.6M | ||
| Q3 25 | — | $62.1M | ||
| Q2 25 | — | $53.3M | ||
| Q1 25 | — | $62.5M | ||
| Q4 24 | — | $75.2M | ||
| Q3 24 | — | $44.2M | ||
| Q2 24 | — | $41.4M | ||
| Q1 24 | — | $40.6M |
毛利率BEAMDOCS
| Q4 25 | — | 89.9% | ||
| Q3 25 | — | 90.3% | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | 89.5% | ||
| Q4 24 | — | 91.6% | ||
| Q3 24 | — | 90.0% | ||
| Q2 24 | — | 89.3% | ||
| Q1 24 | — | 89.4% |
营业利润率BEAMDOCS
| Q4 25 | -15.3% | 38.9% | ||
| Q3 25 | — | 37.8% | ||
| Q2 25 | — | 37.4% | ||
| Q1 25 | — | 35.2% | ||
| Q4 24 | — | 47.4% | ||
| Q3 24 | — | 38.8% | ||
| Q2 24 | — | 36.4% | ||
| Q1 24 | — | 35.5% |
净利率BEAMDOCS
| Q4 25 | 214.1% | 33.3% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | 36.5% | ||
| Q1 25 | — | 45.2% | ||
| Q4 24 | — | 44.6% | ||
| Q3 24 | — | 32.3% | ||
| Q2 24 | — | 32.7% | ||
| Q1 24 | — | 34.4% |
每股收益（稀释后）BEAMDOCS
| Q4 25 | $2.53 | $0.31 | ||
| Q3 25 | — | $0.31 | ||
| Q2 25 | — | $0.27 | ||
| Q1 25 | — | $0.31 | ||
| Q4 24 | — | $0.37 | ||
| Q3 24 | — | $0.22 | ||
| Q2 24 | — | $0.21 | ||
| Q1 24 | — | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $64.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $979.3M |
| 总资产 | $1.5B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMDOCS
| Q4 25 | $1.2B | $64.8M | ||
| Q3 25 | — | $169.2M | ||
| Q2 25 | — | $137.3M | ||
| Q1 25 | — | $209.6M | ||
| Q4 24 | — | $165.3M | ||
| Q3 24 | — | $184.2M | ||
| Q2 24 | — | $111.4M | ||
| Q1 24 | — | $96.8M |
股东权益BEAMDOCS
| Q4 25 | $1.2B | $979.3M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $961.2M | ||
| Q2 24 | — | $913.6M | ||
| Q1 24 | — | $901.4M |
总资产BEAMDOCS
| Q4 25 | $1.5B | $1.2B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | 0.99× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMDOCS
| Q4 25 | $-83.3M | $60.9M | ||
| Q3 25 | — | $93.9M | ||
| Q2 25 | — | $62.1M | ||
| Q1 25 | — | $98.5M | ||
| Q4 24 | — | $65.2M | ||
| Q3 24 | — | $68.3M | ||
| Q2 24 | — | $41.2M | ||
| Q1 24 | — | $63.9M |
自由现金流BEAMDOCS
| Q4 25 | $-87.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率BEAMDOCS
| Q4 25 | -76.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度BEAMDOCS
| Q4 25 | 3.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率BEAMDOCS
| Q4 25 | -0.34× | 0.99× | ||
| Q3 25 | — | 1.51× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | 1.58× | ||
| Q4 24 | — | 0.87× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | — | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
